Adagene Inc.
NASDAQ:ADAGBiotechnology
Healthcare
$2.01 +3.68%
+$0.13 today
- Market cap
- $75.67M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
52W Low $1.30High $4.75
Volume 1.18M
Average 0.21M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$15.66M
FY 2025 · Annual
Investing Cash Flow
$476,803.00
FY 2025 · Annual
-57.0% YoYFinancing Cash Flow
$4.45M
FY 2025 · Annual
+17.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.18M) | (79.97M) | (18.95M) | (33.42M) | (17.61M) |
| Depreciation & Amortization | 1.13M | 1.45M | 1.21M | 926.25K | 589.79K |
| Deferred Income Tax | 622.43K | (44.16K) | 0 | 0 | 0 |
| Stock-Based Compensation | 18.68M | 10.52M | 7.27M | 4.91M | 3.74M |
| Change in Working Capital | 9.35M | 21.94M | (16.55M) | (1.89M) | (775.3K) |
| Accounts Receivables | (3M) | 6.89M | 397.41K | 213.72K | (9.04K) |
| Inventory | 6.02M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.51M | 344.51K | (572.37K) | 1.15M | (1.36M) |
| Other Working Capital | 4.82M | 14.75M | (16.38M) | (3.25M) | 591.01K |
| Other Non-Cash Items | (9.95K) | (2.5M) | (1.44M) | (222.24K) | (1.6M) |
| Operating Cash Flow | (43.41M) | (48.61M) | (28.45M) | (29.7M) | (15.66M) |
| Capital Expenditures | (2.51M) | (690.94K) | (85.01K) | (33.58K) | (17.05K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (47M) | (128.5M) | (80M) |
| Sales of Investments | 0 | 0 | 47M | 129.64M | 80.49M |
| Other Investing Activities | 0 | 4.89K | 7.66K | 169 | 1.4K |
| Investing Cash Flow | (2.51M) | (686.05K) | (77.36K) | 1.11M | 476.8K |
| Debt Repayment | (702.86K) | 21.48M | (5.37M) | (3.42M) | (12.24M) |
| Common Stock Issued | 149.79M | 0 | 5.5K | 7.33M | 138.28K |
| Common Stock Repurchased | (2.36M) | (3.98M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.37M) | 323.21K | 5.5K | (137.3K) | 0 |
| Financing Cash Flow | 145.36M | 17.82M | (5.37M) | 3.77M | 4.45M |
| Effect of Forex Changes | (192.35K) | 842.2K | 74.72K | 81.88K | 64.55K |
| Net Change in Cash | 99.24M | (30.63M) | (33.82M) | (24.74M) | (10.67M) |
| Free Cash Flow | (45.92M) | (49.3M) | (28.54M) | (29.73M) | (15.67M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$17.6M
+ D&A$589.8K
+ Stock-Based Comp$3.7M
+ Deferred Tax$0
- Working Capital-$775.3K
- Other Non-Cash-$1.6M
= Operating Cash Flow-$15.7M
- Capex-$17.1K
= Free Cash Flow-$15.7M
Analysis
FY2025 free cash flow is -$15.7M. FCF conversion is 89.0% of net income. Operating cash flow was -$15.7M, with capex of -$17.1K. The largest bridge item is Stock-Based Comp at $3.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 6-K | 6-K filing | Sep 25, 2026 | |
| 6-K | 6-K filing | Sep 22, 2026 |
Does ADAG generate free cash flow?
Adagene Inc. (ADAG) generated -$15.67M of free cash flow in fiscal 2025.
How much operating cash flow does ADAG produce?
Operating cash flow was -$15.66M, before capital expenditures of $17,053.00.
Continue the stock analysis
Jump to another research area for this company.